Elcosanoid Active Ingredients TRIZ Cases

Auxochrome-conjugated pro-resolving mediators help clear infection, limit neutrophil tissue damage, and avoid immune suppression.

Small molecules such as SL 327 drive fibroblast proliferation and protein secretion to improve wound healing and reduce scarring.

Basic-buffer indolium oligomers stabilize hydrophobic drugs during nanoprecipitation, enabling high loading and stable nanoparticle size over time.

Intact milk fat globules encapsulate DHA and convert it into stable anti-inflammatory oxylipins, improving oral bioavailability.

Combining lubiprostone with CFTR correctors and potentiators boosts chloride transport and lung function in residual-function mutations.

Co-administering insulin with vasoactive agents at the same injection site boosts blood flow, speeds absorption, and improves postprandial glycemic control.

Dual COX-2 and sEH inhibition suppresses cytokine and lipid surges to limit organ damage when direct cytokine-targeted therapies fall short.

Highly purified EPA-FFA reduces UC inflammation while increasing IL-10 and SOCS3 and modulating intestinal microbiota.

Compounds inhibit FKBP51 interaction with the progesterone receptor to delay idiopathic preterm birth and address fetal growth restriction.

This case combines SPMs, active precursors, and acetylsalicylic acid to restore inflammatory balance and ease persistent symptoms.

A PGE2 receptor agonist activates the cAMP pathway to stabilize beta-catenin and drive tissue growth.

Combining prostacyclin with mesenchymal stem cells to treat vasculopathy.

Pyrimidoheterocyclic compounds resolve KRAS druggability limits by accommodating diverse mutations like G12D and G12V via structural versatility.

Adjusting the gelatin coating pH to 7.0-9.5 with buffers prevents acid-catalyzed decomposition of statins while maintaining solubility.

15-hydroxy eicosapentaenoic acid removes liver fat deposits to treat non-alcoholic fatty liver disease.

Cardiac glycosides inhibit sodium-potassium transport in Na+-K+ ATPase, reducing off-target toxicity while treating STK11-mutant cancer.

A pharmaceutical composition using 15-hydroxyeicosapentaenoic acid as the primary active ingredient to treat fibrosis.

Citrate complexes ionic zinc to prevent aggregation, allowing monomeric insulin to achieve faster glucose lowering while maintaining chemical stability.

Eicosapentaenoic acid co-administration reduces triglycerides while maintaining rosiglitazone plasma concentration.

Merging multiple injections into one administration via a slow-release polymer reduces treatment duration while sustaining follicular growth.

Supercritical extraction concentrates SPMs from crude lipids, lowering production costs while maintaining therapeutic purity.

Biodegradable polymer matrices deliver osteogenic compounds locally, preventing ectopic ossification and reducing recovery time.

Pyrimidine derivatives inhibit ALK tyrosine kinase to treat malignancies like neuroblastoma.

Prostaglandin E2 activates protein kinase A to increase hematopoietic stem cell populations in vitro and in vivo.

Selective prostaglandin EP2 receptor agonists activate anti-labour cyclic AMP pathways while blocking pro-inflammatory G protein signals.